$INTI
Inhibitor Therapeutics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000119312518223200 Filed on July 23, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $400.1K $360.0K $280.0K
YoY Change 60.03% 28.57% -61.11%
% of Gross Profit
Research & Development $775.4K $528.9K $440.8K
YoY Change 78.86% 19.99% -27.21%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.176M $884.4K $719.4K
YoY Change 72.58% 22.93% -45.91%
Operating Profit -$1.176M -$884.4K -$719.4K
YoY Change 72.58% 22.93% -45.91%
Interest Expense $4.000K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.172M -$880.0K -$720.0K
YoY Change 72.28% 22.22% -45.86%
Income Tax
% Of Pretax Income
Net Earnings -$1.172M -$881.9K -$716.4K
YoY Change 72.52% 23.1% -46.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.167K $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 370.0M shares 369.7M shares 369.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.441M $800.0K $1.640M
YoY Change 61.89% -51.22% -64.5%
Cash & Equivalents $1.441M $795.8K $1.643M
Short-Term Investments
Other Short-Term Assets $51.44K $290.0K $290.0K
YoY Change -82.85% 0.0% 477.45%
Inventory
Prepaid Expenses $51.44K $41.06K $40.98K
Receivables
Other Receivables
Total Short-Term Assets $1.742M $1.087M $1.934M
YoY Change 46.49% -43.82% -58.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.32K $97.64K $126.9K
YoY Change -24.49% -23.08% -49.23%
Total Long-Term Assets $90.32K $97.64K $126.9K
YoY Change -24.49% -23.08% -49.23%
TOTAL ASSETS
Total Short-Term Assets $1.742M $1.087M $1.934M
Total Long-Term Assets $90.32K $97.64K $126.9K
Total Assets $1.833M $1.184M $2.061M
YoY Change 40.01% -42.54% -58.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $328.0K $326.2K $322.3K
YoY Change 50.0% 1.21% -18.62%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $549.1K $461.9K $339.6K
YoY Change 117.71% 36.02% -45.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $549.1K $461.9K $339.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $549.1K $461.9K $339.6K
YoY Change 117.71% 36.02% -45.06%
SHAREHOLDERS EQUITY
Retained Earnings -$51.60M -$50.38M -$46.69M
YoY Change 8.94% 7.91% 20.66%
Common Stock $48.93M $48.74M $48.41M
YoY Change 1.03% 0.69% 12.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.677M -$1.638M $1.722M
YoY Change
Total Liabilities & Shareholders Equity $1.833M $1.184M $2.061M
YoY Change 40.01% -42.54% -58.06%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$1.172M -$881.9K -$716.4K
YoY Change 72.52% 23.1% -46.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$956.2K -$790.0K -$740.0K
YoY Change 25.81% 6.76% -26.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.603M 10.00K 50.00K
YoY Change -80.0% -99.09%
NET CHANGE
Cash From Operating Activities -956.2K -790.0K -740.0K
Cash From Investing Activities
Cash From Financing Activities 1.603M 10.00K 50.00K
Net Change In Cash 646.7K -780.0K -690.0K
YoY Change -185.09% 13.04% -115.37%
FREE CASH FLOW
Cash From Operating Activities -$956.2K -$790.0K -$740.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
369959064 shares
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1643407
CY2018Q2 us-gaap Assets Current
AssetsCurrent
1086815
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48707702
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
326193
CY2018Q2 us-gaap Assets
Assets
1184453
CY2018Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
795757
CY2018Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
500000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369599266 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369774266 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
36977
CY2018Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2018Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
56548
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
461886
CY2018Q2 us-gaap Liabilities
Liabilities
461886
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1184453
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97638
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41058
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
79145
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50382978
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-1638299
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2017Q4 us-gaap Assets Current
AssetsCurrent
655768
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48403523
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
534956
CY2017Q4 us-gaap Assets
Assets
768052
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369599266 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369774266 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
36960
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
601489
CY2017Q4 us-gaap Liabilities
Liabilities
601489
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768052
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
112284
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61655
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
66533
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48273920
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5242015
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2273408
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34765
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14640
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
31446
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3628227
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1613788
us-gaap Net Income Loss
NetIncomeLoss
-3517868
us-gaap Operating Expenses
OperatingExpenses
3532508
us-gaap Operating Income Loss
OperatingIncomeLoss
-3532508
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
49500
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1259100
us-gaap Share Based Compensation
ShareBasedCompensation
1837869
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
363595602 shares
hppi Net Settlement In Connection With Issuance Of Shares Associated With Restricted Stock Units
NetSettlementInConnectionWithIssuanceOfSharesAssociatedWithRestrictedStockUnits
3677727
hppi Fair Value Of Shares Withheld With Net Settlement Transaction
FairValueOfSharesWithheldWithNetSettlementTransaction
3677727
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3517868
dei Amendment Flag
AmendmentFlag
false
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
292196
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
451644
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
56548
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
us-gaap Dividends Preferred Stock
DividendsPreferredStock
56548
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
856377
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-35243
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6712
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-196151
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2372866
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1921222
us-gaap Net Income Loss
NetIncomeLoss
-2052510
us-gaap Operating Expenses
OperatingExpenses
2059222
us-gaap Operating Income Loss
OperatingIncomeLoss
-2059222
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1202845
us-gaap Share Based Compensation
ShareBasedCompensation
292196
dei Trading Symbol
TradingSymbol
HPPI
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369669708 shares
hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
2360866
hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
0
hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
12000
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2109058
hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
56548
hppi Stock Issued During Period Shares New Issues To Related Party
StockIssuedDuringPeriodSharesNewIssuesToRelatedParty
0 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
278674
CY2017Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2995
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-716441
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
719436
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-719436
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
440762
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369481409 shares
CY2017Q2 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-716441
CY2018Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
29918
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
355531
CY2018Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2490
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-881916
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
884406
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-884406
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
528875
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369723717 shares
CY2018Q2 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-911834

Files In Submission

Name View Source Status
0001193125-18-223200-index-headers.html Edgar Link pending
0001193125-18-223200-index.html Edgar Link pending
0001193125-18-223200.txt Edgar Link pending
0001193125-18-223200-xbrl.zip Edgar Link pending
d557556d10q.htm Edgar Link pending
d557556dex311.htm Edgar Link pending
d557556dex312.htm Edgar Link pending
d557556dex321.htm Edgar Link pending
d557556dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20180630.xml Edgar Link completed
hppi-20180630.xsd Edgar Link pending
hppi-20180630_cal.xml Edgar Link unprocessable
hppi-20180630_def.xml Edgar Link unprocessable
hppi-20180630_lab.xml Edgar Link unprocessable
hppi-20180630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending